Beyond Living Donor Kidney Transplantation in COL4 Nephropathy - A Real-World Clinical Dilemma in Light of Current Guidelines
References
- Abecassis, M.; Bartlett, S.T.; Collins, A.J.; Davis, C.L.; Delmonico, F.L.; Friedewald, J.; Hays, R.; Howard, A.; Jones, E.; Leichtman, A.B.; et al. Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin. J. Am. Soc. Nephrol. 2008, 3, 471–480.
- Thomas CP, Daloul R, Lentine KL, et al. Genetic evaluation of living kidney donor candidates: A review and recommendations for best practices. Am J Transplant. 2023;23(5):597–607.
- Boenink R, Kramer A, Tuinhout RE, Savoye E, Åsberg A, Idrizi A, et al. Trends in kidney transplantation rate across Europe: study from the ERA Registry. Nephrol Dial Transplant. 2023;38(6):1528–1539.
- Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017;101(8 Suppl 1):S1–S109.
- Torra R, Lipska-Ziętkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E, et al. Diagnosis, management and treatment of Alport syndrome: 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025;40(6):1091–1106.
- Kang E, Park BH, Lee H, Kang HG, Kim JH, Kim YN, Jung Y, Rim H, Shin HS. A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Res Clin Pract. 2025;44(4):566–575.
- Gjorgjievski N, Karanfilovski V, Stojanoska A, Shterjova-Markovska Z, Gjorgievska J, Arsov T, Hoefele J, Tasic V, Abazi N, Nikolov I. Extrarenal manifestations as clinical markers for early initiation of renal replacement therapy in COL4 nephropathy. Nephrol Dial Transplant. 2025;40(Suppl 3):gfaf116.1048.
- Mallett A, Tang W, Clayton PA, Stevenson S, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Campbell SB, Johnson DW. End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrol Dial Transplant. 2014;29(12):2277–2286.
- Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, et al. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol. 2012;7(12):1969–1976.
- Kelly YP, Patil A, Wallis L, Murray S, Kant S, Kaballo MA, Casserly L, Doyle B, Dorman A, O’Kelly P, Conlon PJ. Outcomes of kidney transplantation in Alport syndrome compared with other forms of renal disease. Ren Fail. 2017;39(1):290–293.
- Boenink R, Bonthuis M, Boerstra BA, Astley ME, Montez de Sousa IR, Helve J, et al. The ERA Registry Annual Report 2022: Epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons. Clin Kidney J. 2024;18(2):sfae405.
- Bonthuis M, Kramer A, Bakkaloğlu SA, Helve J, Gjorgjievski N, Resic H, Åsberg A, Mitsides N, Dębska-Ślizień AM, Komissarov KS, Kuzema V, Seyahi N, Ponte B, Ziginskiene E, Lausevic M, Rychlík I, Ots-Rosenberg M, Vazelov E, Moustakas G, Okša A, Strakosha A, Garneata L, Katicic D, Torra R, Ortiz A, Stel VS. Incidence and prevalence of kidney replacement therapy in central and eastern europe -trends from the ERA registry. Nephrol Dial Transplant. 2026 Jan 7:gfaf268.
- Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of the collagen IV α345 network. Kidney Int. 2018;93(5):1048–1060.
- Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants are common and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. 2022;7(9):1933–1938.
- Katayama K, Nishikawa K, Hane A, Fujimoto M, Saiki R, Murata T, Inoue T, Dohi K. Mother–son kidney transplantation in patients with X-linked Alport syndrome. Kidney Int Rep. 2021;6(5):1454–1458.
- Sakai K, Muramatsu M, Ogiwara H, Kawamura T, Arai K, Aikawa A, Ohara T, Mizuiri S, Joh K, Naito I, Hasegawa A. Living related kidney transplantation in a patient with autosomal recessive Alport syndrome. Clin Transplant. 2003;17(Suppl 10):4–8.
- Gross O, Weber M, Fries JWU, Müller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrol Dial Transplant. 2009;24(5):1626–1630.
- Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and uncertainty. Lancet. 2015;385(9981):2003–2013.
DOI: https://doi.org/10.2478/bjmg-2025-00022 | Journal eISSN: 2199-5761
Language: English
Page range: 25 - 28
Published on: May 14, 2026
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2026 V Karanfilovski, Z Shterjova Markovska, A Canevska Taneska, V Tasic, D Plaseska-Karanfilska, N Trpevska Shekerinov, I Nikolov, N Gjorgjievski, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.